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Abstract 
Background: The genome of multiple myeloma (MM) cells is extremely unstable, characterized by a complex com-
bination of structure and numerical abnormalities. It seems that there are several “myeloma subgroups” which differ 
in expression profile, clinical manifestations, prognoses and treatment response. In our previous work, the list of 35 
candidate genes with a known role in carcinogenesis and associated with centrosome structure/function was used 
as a display of molecular heterogeneity with an impact in myeloma pathogenesis. The current study was devoted to 
establish a risk stratification model based on the aforementioned candidate genes.
Methods: A total of 151 patients were included in this study. CD138+ cells were separated by magnetic-activated 
cell sorting (MACS). Gene expression profiling (GEP) and Interphase FISH with cytoplasmic immunoglobulin light 
chain staining (cIg FISH) were performed on plasma cells (PCs). All statistical analyses were performed using freeware 
R and its additional packages. Training and validation cohort includes 73 and 78 patients, respectively.
Results: We have finally established a model that includes 12 selected genes (centrosome associated gene pattern, 
CAGP) which appears to be an independent prognostic factor for MM stratification. We have shown that the new 
CAGP model can sub-stratify prognosis in patients without TP53 loss as well as in IMWG high risk patients’ group.
Conclusions: We assume that newly established risk stratification model complements the current prognostic panel 
used in multiple myeloma and refines the classification of patients in relation to the disease risks. This approach can 
be used independently as well as in combination with other factors.
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Background
Multiple myeloma (MM) is a lymphoproliferative dis-
ease characterized by the clonal expansion of neoplas-
tic plasma cells within the bone marrow. The genome of 
the malignant plasma cells is extremely unstable, char-
acterized by a complex combination of structure and 
numerical abnormalities. These abnormalities serve as 
background for large variability in clinical course and 
outcome of MM patients [1]. A multistep process of 
malignant transformation can explain the presence of 
these genetic and clinical heterogeneities, which is admit-
tedly associated with cell cycle deregulation.
Although several staging systems based on clinical 
and laboratory tests have been developed for MM [2, 3], 
standard prognostic factors, such as β2-microglobulin, 
albumin and C-reactive protein, account for only 15–20 
per cent of outcome heterogeneity [4]. Previously, con-
ventional cytogenetics was recognized as a relevant prog-
nostic tool in multiple myeloma. Nevertheless, in spite of 
advances in molecular cytogenetics, many others unde-
fined abnormalities forming genetic complexity in MM 
may still exist [5].
In our previous studies, we have used gene expression 
profiling to analyze a set of genes involved in formation 
of centrosome abnormalities in MM. Taking into con-
sideration that centrosome amplification is common in 
all stages of plasma cell neoplasia [6] and is therefore an 
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instability [7, 8]. Centrosome associated molecular sig-
nature is related to overall survival as well as to clinical 
parameters and ISS staging in MM [9]. We have identified 
a gene pattern, which was used as a display of molecular 
heterogeneity with an impact on myeloma pathogenesis 
[10].
We believe that the analysis of molecular signature 
will supplement existing prognostic models based 
on screening of chromosomal aberrations in plasma 
cells. Thus, the objective of our study was to create 
and validate risk stratification model based on previ-




A total of 151 patients with MM enrolled in Univer-
sity Hospital Brno, Czech Republic, University Hospital 
Olomouc, Czech Republic and University Hospital Bra-
tislava, Slovakia, were included in this study. The study 
was approved by the Ethical Committee of the Faculty 
of Medicine, Masaryk University (chairman: Josef Kure, 
PhD; ref number: 14/2009 and 29/2011), and the study 
was conducted according to the Helsinki declaration. 
All patients provided written informed consent. Train-
ing and validation cohort includes 73 and 78 patients, 
respectively. Patients’ baseline characteristics are sum-
marized in Table 1.
The bone marrow of patients was obtained dur-
ing routine diagnostic procedure. Plasma cells in 
mononuclear cell fraction were enriched by anti-
CD138+  immunomagnetic beads and sorted using 
AutoMACS (Miltenyi Biotec). Purity of CD138 + frac-
tion was measured by flowcytometry and/or cytospin 
and samples with >80 % plasma cells were provided for 
total RNA isolation.
Gene expression profiling (GEP)
Total RNA was isolated using QIAGEN RNeasy Mini Kit. 
RNA isolation. purification, and microarray hybridization 
has been reported previously [11]. Total RNA with purity 
ratio 260/280 >1.7 and integrity (RIN) >7.5 (as measured 
by Agilent 2100 Bioanalyzer) was transcribed into cDNA 
(Ambion WT Expression Kit), labeled and hybridized to 
the Affymetrix GeneChip® Human Gene ST 1.0 array 
and further processed through R/Bioconductor frame-
work by oligo package. RMA normalized data at gene 
level were statistically analyzed. Generated CEL files of 
patients included in this study have been deposited in the 
ArrayExpress Archive database under accession number 
E-MTAB-1038 for training set and E-MTAB-4032 for 
validation set. Both are available online (http://www.ebi.
ac.uk/arrayexpress/).
Fluorescence in situ hybridization (FISH)
FISH was performed as a part of routine diagnostic pro-
cedure as previously described [12]. The following aber-
rations were studied: 1q21 gain, 13q14 deletion, 17p13 
deletion and translocation t(4;14). Hyperdiploidy status 
was determined with commercial probes mapping to 
chromosome 5 (LSI D5S23/D5S721), 9 (CEP9) and 15 
(CEP15) (Abbott Molecular, Des Plaines, IL, USA).
Statistical analysis
All statistical analyses were performed using freeware R 
and its additional packages: oligo, affy, survival, nnet and 
pROC [13–15]. Training and validation cohort includes 
73 and 78 patients, respectively. Both cohorts have no 
significant differences in basic clinical parameters and 
all continuous variables were tested by nonparametric 
Mann–Whitney test. For categorical variables, the Fisher 
exact test was used. Overall survival (OS) was calculated 
from the date of diagnosis to death; progression free sur-
vival (PFS) was defined by the date of diagnosis and the 
date of disease progression or any death; time to pro-
gression (TTP) was defined by the date of diagnosis and 
the date of disease progression or disease-related death. 
Survival rates were estimated using the Kaplan–Meier 
method. Differences in survival of patients’ subgroups 
were compared using the log-rank test. p values below 
0.05 were considered statistically significant.
Results
In our previous study [9], a set of 111 genes with a known 
role in oncogenesis associated with centrosomal struc-
ture/function abnormalities corresponding to their pro-
teins were selected for hierarchical clustering of gene 
expression (RMA-normalized, log 2 transformed expres-
sion level) profiles on CD138+  plasma cells from 73 
patients with multiple myeloma. Furthermore, clustering 
analysis revealed a pattern of 35 genes. These genes and 
patients were later re-clustered to reveal three subgroups 
of patients according to different expression patterns of 
the chosen genes: “high expressed,” “medium expressed” 
and “low expressed,” respectively.
The list of 35 initially identified candidate genes 
were utilized for the generation of 3-subgroup pre-
dictor. To discover the gene signature that is able to 
predict subgroup membership of each sample, the 
bidirectional stepwise selection procedure with multi-
nomial logistic regression model was performed. The 
best model was selected due to the Akaike informa-
tion criteria. To apply such procedure, 12 candidate 
genes (BUB1, BUB1B|PAK6, RAD51, PLK1, BRCA1, 
CENPA, BARD1, AURKA, MAD2L1, CENPH, XRCC2 
and CDC25C|FAM53C) were identified and coefficients 
of multinomial regression model were estimated. The 
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suggested regression model allows to predict the group-
ing of samples from both training and validation cohort 
into one of the subgroups (“high expressed,” “medium 
expressed” or “low expressed”). The pseudocode of pre-
dictive analyses and expression level of candidate genes 
are available in Additional files 1 and 2.
Based on this centrosome associated genes pat-
tern (CAGP) model, patients were stratified into three 
groups—“High expressed”, “Medium expressed” and 
“Low expressed”. The overall survival of patients in “High 
expressed” and “Medium expressed” subgroups was sig-
nificantly worse than in patients in “Low expressed” sub-
group for both training and validation cohorts (Fig.  1) 
and was in concordance with previously published results 
[9]. Analysis of progression free survival (PFS) and time 
to progression (TTP) in the three CAGP expression 
Table 1 Patients’ baseline characteristic
CR complete response; VGPR very good partial response; PR partial response; MR minimal response; SD stable disease; PG progression
a Both cohorts have no significant difference in basic clinical parameters
Training cohorta Validation cohorta
No. of patients 73 78
Follow-up median (min–max) [month] 23.6 (0.3–97.0) 18.6 (0.1–250.0)
Gender: males–females 49.3–50.7 % 55.1–44.9 %
Age median (range) [years] 69 (38–84) 66 (40–90)
ISS stage: I–II–III 28.8 %–27.3 %–43.9 % 24.7 %–35.1 %– 40.3 %
Durie-Salmon stage: I–II–III 4.3 %–14.3 %–81.4 % 3.8 %–29.5 %–66.7 %
Durie-Salmon substage: A–B 81.4 %–18.6 % 75.6 %–24.4 %
Ig isotype: IgG–IgA–FLC-Non-secr. 60.3 %–23.5 %–16.2 % 57.7 %–28.2 %–1.3 %–12.8 %
Light chains: kapp–lambda 58.0 %–42.0 % 53.8 %–46.2 %
Plasma cell infiltration in bone marrow 34.4 % (0.8 %–93.6 %) 36.0 % (2.2 %–81.2 %)
No. of previous treatment lines
 None (first line treatment) 57.7 % (41/71) 64.1 % (50/78)
 One 19.7 % (14/71) 15.4 % (12/78)
 Two 8.5 % (6/71) 10.3 % (8/78)
 More (>2) 14.1 % (10/71) 10.3 % (8/78)
Treatment regimen
 Bortezomib-based 47.8 % (32/67) 64.9 % (50/77)
 Thalidomide-based 14.9 % (10/67) 10.4 % (8/77)
 Lenalidomide-based 25.4 % (17/67) 18.2 % (14/77)
 Others 11.9 % (8/67) 6.5 % (5/77)
Treatment response
 CR-VGPR-PR-MR-SD-PG 12.3 %–29.8 %–22.8 %–5.3 %–5.3 %–26.3 % 10.8 %–20.0 %–27.7 %–7.7 %–4.6 %–29.2 %
Biochemical parameters
 Hemoglobin (g/l) 105.5 (67.0–151.0) 95.5 (65.9–146.0)
 Thrombocytes (×109) 192.0 (33.0–416.0) 188.5 (55.0–485.0)
 Calcium (mmol/l) 2.29 (1.74–23.37) 2.32 (1.75–2.78)
 Albumin (g/l) 38.2 (21.1–54.1) 35.7 (17.4–52.2)
 Creatinine (umol/l) 98.5 (53.0–783.0) 94.5 (30.0–849.0)
 β2-microglobulin (mg/l) 4.70 (1.79–42.60) 4.61 (1.62–50.0)
 Lactate dehydrogenase (ukat/l) 3.72 (1.53–22.92) 3.36 (1.14–7.77)
 C-reactive protein (mg/l) 3.6 (0.0–174.3) 4.0 (0.0–149.3)
 Monoclonal Ig (g/l) 29.8 (0.0–92.6) 30.2 (0.0–85.6)
Chromosomal abnormality
 Deletion 13q14 49.2 % (30/61) 60.0 % (39/65)
 Deletion 17p13 8.3 % (5/60) 13.8 % (9/65)
 Translocation t(4;14) 46.9 % (15/32) 44.4 % (16/36)
 Amplification 1q21 56.9 % (37/65) 54.5 % (36/66)
 Hyperdiploidy (H-MM) 45.5 % (30/66) 47.0 (17/46)
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groups did not reveal any significant differences (data not 
shown).
Additionally, we combined patients with worse over-
all survival and clinical characteristics in High- and 
Medium- expressed subgroups as “HR CAGP” (high risk 
centrosome associated genes pattern). Patients with Low 
expressed were defined as “LR CAGP” (low risk centro-
some associated genes pattern), respectively. Signifi-
cantly worse prognosis was found for HR CAGP group 
(HR = 1.8; 3-year OS = 25.1 %) compared to LR CAGP 
group (3-year OS = 53.8 %, p < 0.01). Analysis of PFS and 
TTP in two CAGR risk groups did not reveal any signifi-
cant differences (Fig. 2).
To characterize the prognostic significance of CAGP 
model, multivariate Cox proportional hazards sur-
vival model was used. Besides CAGP, the following 
parameters were used for multivariate Cox proportional 
hazards survival model: ISS stage, β2-microglobulin, 
del 17p13, t(4;14), amp 1q21. The variables in the mul-
tivariate model were the only variables, which remained 
statistically significant when potential predictors were 
combined together including CAGP, which was forced 
into the model. Among all subsequently tested com-
binations of predictors, the best results in risk of death 
assessment were obtained for CAGP combined with 
del 17p13 (p  <  0.001). It is worth to mention that both 
prognostic factors were independent. “HR” CAGP sub-
group as well as TP53 deletion had significantly higher 
risk of death assessment (HR  =  1.8 and HR  =  2.5, 
respectively; p  <  0.005). Survival characteristics for dif-
ferent risk sub-groups are presented in Table  2. Appar-
ent controversies in sub-stratified TP53 deletion groups 
Fig. 1 Overall survival of three CAGP expression groups of MM patients. a Kaplan–Meier curves for OS of training patients’ cohort (n = 73) strati-
fied by centrosome associated gene pattern (CAGP). b Kaplan–Meier curves for OS of validation patients’ cohort (n = 78) stratified by centrosome 
associated gene pattern (CAGP). c Kaplan–Meier curves for OS of jointed training and validation patients’ cohort (n = 151) stratified by centrosome 
associated gene pattern (CAGP)
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probably associated with small cohort size (7 patients in 
each TP53+/low risk CAGP and TP53+/high risk CAGP 
sub-groups).
Further analysis includes comprising of CAGP model 
and International Myeloma Working Group (IMWG) 
risk stratification model [16, 17]. Briefly, IMWG con-
sensus recommendations includes the following mak-
ers: serum β2-microglobulin, serum albumin, t(4;14), 
17p13 and 1q21 by FISH. Using this combination, high-
risk patients will survive less than 2 years despite novel 
agents, and low-risk patients can survive for more than 
10 years [16]. In total, 70 patients had sufficient clinical 
data to be included to the analysis. To the IMWG High 
and Standard Risk groups belong 28 and 41 patients 
respectively. The only one patient belongs to IMWG 
Low Risk group was excluded from the further analysis.
Fisher exact test did not show significance of the asso-
ciation (contingency) between the two kinds of risk 
classification (p = 0.55). Thus, CAGP model can be used 
to sub-stratify IMWG risk groups. Survival characteris-
tics for Standard and High Risk IMWG groups sub-strat-
ified with CAGP model are presented in Table 3.
Data shows that proposed CAGP model can be used 
to sub-stratify IMWG High risk group. This statement 
is relevant for overall survival, progression-free survival 
and time to progression.
Discussion
The role of genes is a potential for the determination 
of molecular signature as a genetic based prognostic or 
predictive marker, but it is still currently unclear. High- 
and low-risk groups defined with cytogenetic prognostic 
models that is based on the most important chromo-
somal abnormalities such as deletion 17p13 (TP53 gene), 
translocation t (4;14) and gain 1q21, are still heteroge-
neous [18, 19]. Heterogeneity determined by molecular 
Fig. 2 Overall survival, progression free survival and time to progression in CAGP risk groups of MM patients. a Kaplan–Meier curves for OS of com-
bined training and validation patients’ cohort (n = 151) stratified by centrosome associated gene pattern (CAGP). b Kaplan–Meier curves for PFS of 
combined training and validation patients’ cohort (n = 151) stratified by centrosome associated gene pattern (CAGP). c Kaplan–Meier curves for TTP 
of combined training and validation patients’ cohort (n = 151) stratified by centrosome associated gene pattern (CAGP)
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variability also determines the diversity of disease at clin-
ical level. It seems that there are several “myeloma sub-
groups” which differ in expression profile and in clinical 
manifestations, i.e., prognosis and response for treatment 
[20]. Until now, approximately 10 % of low-risk patients 
relapse in 2  years whereas a reverse tendency can be 
observed in high-risk group as 5–10 % do not reach early 
relapse (our unpublished data). In spite of substantial 
progress in therapeutics, the outcome for patients requir-
ing therapy is still highly variable.
In our previous work, we identified the list of 35 candi-
date genes that play a known role in carcinogenesis and 
associated with centrosome structure/function, which 
was used to display molecular heterogeneity with an 
impact on myeloma pathogenesis [9]. The current study 
was devoted to create and validate risk stratification 
model based on these centrosome associated candidate 
genes. Finally, the created model including 12 selected 
genes (centrosome associated gene pattern) appears to be 
an independent prognostic factor for MM stratification.
Nowadays, however, it is needed to use an integrated 
genomics approach to develop a comprehensive model for 
risk stratification [21], as GEP-based signature alone appears 
to have limited power for prognosis in MM [22]. We believe 
that stratification models reflecting RNA level (gene expres-
sion profiling) can supply stratification models reflecting 
DNA level (interphase fluorescence in situ hybridization).
We have shown that the combination of two independ-
ent risk factors such as expression of centrosome associ-
ated related genes pattern (CAGP) with TP53 loss depicts 
the best results in death assessment risk stratification. 
We suppose that the stated combination of risk factors 
has become pathogenetically relevant. It may be logically 
explained by affecting the centrosome associated mitotic 
damage, which appears catastrophic in the absence of 
p53-dependent checkpoint response [23, 24].
Table 2 Survival characteristics for different TP53 risk groups sub-stratified with CAGP model
Low risk CAGP” group includes patients with “Low expressed” centrosome associated gene pattern. “High risk CAGP” group includes patients with united “High and 
medium expressed” centrosome associated gene pattern. “TP53+” group includes patients with deletion 17p13; “TP53−” group includes patients without deletion 
17p13 (positivity cut-off >20 %)






 Low risk CAGP 66 38.8 53.8 <0.00799
 High risk CAGP 84 1.8 (1.16; 2.80) 22.1 25.1
 TP53− 110 25.1 35.6 <0.00281
 TP53+ 14 2.5 (1.35; 4.73) 12.8 12.2
 TP53−/low risk CAGP 47 38.8 61.1 <0.00099
 TP53−/high Risk CAGP 63 2.5 (1.41; 4.30) 22.2 20.1
 TP53+/low Risk CAGP 7 12.8 0 <0.3621
 TP53+/high risk CAGP 7 0.5 (0.14; 2.05) 16.7 21.4
Time to progression
 Low risk CAGP 66 13.6 11.5 <0.1939
 High risk CAGP 84 1.3 (0.88; 1.88) 13.0 8.7
 TP53− 110 13.9 11.6 <0.01378
 TP53+ 14 2.1 (1.15; 3.79) 8.7 0
 TP53−/low risk CAGP 47 16.4 15.3 <0.08914
 TP53−/high risk CAGP 63 1.5 (0.94; 2.34) 13.2 8.0
 TP53+/low risk CAGP 7 7.6 0 <0.676
 TP53+/high risk CAGP 7 0.8 (0.23; 2.61) 9.9 0
Progression free survival
 Low risk CAGP 66 12.6 10.8 <0.06232
 High risk CAGP 84 1.4 (0.98; 2.03) 10.2 5.6
 TP53− 110 13.2 8.8 <0.04351
 TP53+ 14 1.8 (1.01; 3.29) 8.7 0
 TP53−/low risk CAGP 47 15.2 14.1 <0.02102
 TP53−/high risk CAGP 63 1.7 (1.07; 2.55) 11.3 4.6
 TP53+/low risk CAGP 7 7.6 0 <0.676
 TP53+/high risk CAGP 7 0.8 (0.23; 2.61) 9.9 0
Page 7 of 9Kryukov et al. J Transl Med  (2016) 14:150 
Summarizing our previously published studies [25], we 
suggest that centrosome dysfunction accomplished with 
safe apoptotic system will reset cell cycle and make such 
clone more sensitive to pro-apoptotic signals. In contrast, 
in case of an affected apoptotic response, centrosome 
dysfunction will cause severe genomic instability, which 
evade apoptosis despite being induced, and may eventu-
ally develop a clone with even more aggressive pheno-
type. Probably, systemic study of apoptotic response in 
concordances with integrative “omics” study of centro-
some machinery will elucidate biological background of 
revealed controversies in sub-stratified TP53 loss groups.
In conclusion, we have created a new GEP-based model 
for classifying every patient into one of two prognostic 
subgroups (high- and low risk CAGP). It seems that CAGP 
model is able to sub-stratify TP53 negative subgroup: 
patients with high expressed CAGP attribute to the group 
with higher risk of death assessment, while patients with 
low expressed CAGP attribute to the group with lower risk 
of death assessment within aforementioned subgroup.
Basic laboratory tests including serum albumin and 
β2-microglobulin for ISS staging, and FISH for t(4;14), del 
17p13 and 1q21 gain are markers risk stratification them-
selves [17, 26]. International Myeloma Working Group 
consensus on risk stratification in multiple myeloma rec-
ommends combination of ISS and FISH for risk stratifi-
cation. This risk model includes serum β2-microglobulin, 
serum albumin, t (4;14), 17p13 and 1q21 by FISH [16]. 
IMWG High Risk group has surviving less than 2  years 
despite novel agents and includes patients with ISS II/
III and t (4;14)/17p13 del. IMWG Standard Risk group 
includes patients with ISS III and no adverse FISH or ISS 
I and t (4;14)/17p13 del. IMWG Low Risk group can sur-
vive for more than 10 years and includes ISS I/II without 
adverse FISH [16, 17]. In our study, cohort of patients 
from IMWG high risk group has overall survival median 
Table 3 Survival characteristics for standard and high risk IMWG groups sub-stratified with CAGP model
“Low risk CAGP” group includes patients with “Low expressed” centrosome associated gene pattern. “High risk CAGP” group includes patients with united “High and 
medium expressed” centrosome associated gene pattern. “IMWG standard risk” group includes patients with ISS III and no adverse FISH or ISS I and t(4;14)/17p13 del; 
“IMWG high risk” group includes patients with ISS II/III and t(4;14)/17p13 del
Stratification group N HR (95 % CI) Survival median (months)3-years outcome (%) p value (log-rank)
Overall survival
 Low risk CAGP 66 38.8 53.8 <0.00799
 High risk CAGP 84 1.8 (1.16; 2.80) 22.1 25.1
 IMWG standard risk 41 22.8 32.1 <0.1371
 IMWG high risk 28 1.6 (0.86; 2.91) 15.8 23.5
 IMWG standard risk/low risk CAGP 18 29.2 42.9 <0.4532
 IMWG standard risk/high risk CAGP 23 1.4 (0.59; 3.25) 22.8 27.4
 IMWG high risk/low risk CAGP 14 16.6 49.9 <0.02836
 IMWG high risk/high risk CAGP 14 2.8 (1.07; 7.45) 11.5 8.2
Time to progression
 Low risk CAGP 66 13.6 11.5 <0.1939
 High risk CAGP 84 1.3 (0.88; 1.88) 13.0 8.7
 IMWG standard risk 41 13.2 6.9 <0.7824
 IMWG high risk 28 1.1 (0.62; 1.89) 12.0 0
 IMWG Standard risk/low risk CAGP 18 12.3 0 <0.9978
 IMWG standard risk/high risk CAGP 23 1 (0.48; 2.07) 14.5 9.6
 IMWG high risk/low risk CAGP 14 17.7 0 <0.05469
 IMWG high risk/high risk CAGP 14 2.3 (0.96; 5.55) 8.0 0
Progression free survival
 Low risk CAGP 66 12.6 10.8 <0.06232
 High risk CAGP 84 1.4 (0.98; 2.03) 10.2 5.6
 IMWG standard risk 41 13.2 6.3 <0.8121
 IMWG high risk 28 1.1 (0.62; 1.84) 11.4 0
 IMWG standard risk/low risk CAGP 18 12.3 0 <0.9395
 IMWG standard Risk/high risk CAGP 23 1 (0.48; 1.97) 13.9 9.1
 IMWG high risk/low risk CAGP 14 17.7 0 <0.0325
 IMWG high risk/high risk CAGP 14 2.5 (1.05; 5.89) 7.7 0
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15.8 month with 3-year survival 23.5 % and correspond-
ing with previously published data [16]. We found no sig-
nificant association between the IMWG and CAGP risk 
classifications. Moreover, CAGP model can be used to 
sub-stratify IMWG High Risk group: patients with high 
expressed CAGP attribute to the group with higher risk 
of death assessment, shorter overall survival, progres-
sion-free survival and time to progression.
Conclusions
We assume that the newly established prognostic stratifi-
cation model complements the current prognostic panel 
used in multiple myeloma and refines the classification of 
patients in relation to the risk of disease. This approach 
can be used independently as well as in combination with 
other factors. Thus, the new model can sub-stratify prog-
nosis in patients without TP53 loss as well as in IMWG 
high risk patients’ group. These findings need to be con-
firmed on a larger cohort with longer follow-up.
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